valu usd unless otherwis note
think magnitud guidanc risk still under-
appreci lower ep
view approach debat continu around
buysid expect guidanc investor wide expect
guidanc move lower midpoint buysid believ
versu street given sever headwind describ
believ risk materi cut lower ep
see high hurdl remain sector perform
lower ep expect
miss meaning cut guidanc rang mid
could effect impair one-tim special performance-
base award key employe ep need
given anticip move level would surpris
see big bath guidanc approach key question
whether re-set expect ev/ebitda help
gener advair given approv delay link could
ep impact also believ street like over-
model gener advair gener ep
morn gsk re-affirmed worsen brand trend
billion without gener billion
initi guid declin leav shrink opportun
also believ gsk go rebat aggress retain share
check point potenti author gener lack gener
restasi approv bridg goal date could add pressur
risk-adjust
base busi us gener total revenu
continu believ reli heavili larg pipelin
opportun backfil us pressur per channel check link
believ prune product spring higher margin north
america revenu limit support
return growth year introduc gross margin headwind
year impli meaning ramp season lower
think unattain bp ep
copaxon share remain subdu like
expect aggress price action
highlight nv call link bring question whether
guidanc reflect overli ambiti expect think like
model modest ep contribut
epipen suppli constraint via press releas warn
intermitt suppli constraint brand/author gener
fda follow link cite multipl factor contribut
limit avail epipen certain area us remind
altern epinephrin product head season peak
back school season impact outlook unclear
price prior trade day market close estimate unless otherwis note
view solid long-term pipelin
diversifi revenu base howev think
immun broader sector challeng pressur
gener sector pressur worsen like
peer lever capit structur limit financi
flexibl continu risk particularli us gener
follow primari driver thesi stock
face mani sector headwind
pressur peer given diversif pipelin
strength view compani favor posit
rel smaller peer
see fewer catalyst near term reduc financi
flexibl least short term
long-term growth outlook still appear stabl
increasingli diversifi global footprint import
addit potenti competit epipen gener
copaxon see lower growth peer
risk view bigger swing factor stock revolv
around convers pipelin drive acceler growth
given breadth opportun drive upsid forecast
miss potenti price chang across core
gener portfolio ramp fda approv outlook versu
model inopportun use cash boost
upcom potenti catalyst event focu
gener advair potenti quick approv
turnaround addit gener copaxon approv
competitor addit accret use capit
bloomberg capit market estim upside/downside/target
base case scenario see stock price impli
price-to-earnings ep ev/ebitda
steadi new gener approv activ low teen us
gener eros base busi
pipelin approv gener restasi gener
advair risk adjust
addit accret though assum
addit debt pay buyback outer year
upsid scenario see valu impli price-to-earnings
ep
inflect higher gener approv activ continu
accret supplement organ growth
portfolio addit debt paydown buyback outer
limit competit high-valu gener greater-
downsid scenario see valu impli p/
 ep
greater price pressur across us gener portfolio
lead gross margin depress
slowdown ou fail off-set pressur us
failur maintain steadi pipelin convers off-set
exhibit
 incom guid flat growth north guid hsd growth eurest guid hsd growth rowoth gener total revenu guid gross profit guid guid total revenuessg guid total revenuesoper incom incom incom tax incom guid incom prefer dividend adjust net guid billionep adjust guid dilut share guid million guid billion growth ebitda analysi net margin guid guid total guid total revenuesoper expens guid net incom pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda use target
multipl gener line specialti peer believ
reflect current sector challeng heighten leverag rel histor level
impli return price target support sector perform rate
risk rate price target
risk rate price target includ limit earlier-than-expect
approv key product advair extend delay accret drive
favor accret addit pipelin surpris
lead global gener manufactur base pittsburgh pennsylvania employ
peopl global compani found transform
last sever year notabl acquisit merck kgaa
compani benefit differ revenu sourc help grow
eu auster headwind us comp strength recent year
